Skip to main content
OpenTrials
Completed

NCT Number: NCT03336567

Perceptions of Cell and Gene Therapies (CGT) for the Treatment of Cancer

Gene and cell therapies have a real value potential (example: potential long-term effect, curative potential, and single administration) but also drawbacks (example: treatment perceived as complex and risky generating fear and anxiety in subjects and their family; high cost) that require significant educational efforts and planning for optimal market access. It is therefore important to understand subject and physician perceptions of T-Cell Receptor (TCR) therapies. The aim of this study is to collect qualitative data from a small but diverse sample of oncologists and subjects in the United States to gather qualitative evidence for a preliminary understanding about their perceptions of T-cell therapies in the treatment of cancer. This cross-sectional study will involve up to 20 adult subjects with cancer and up to 20 oncologists/hematologist-oncologists in the United States. Eligible subjects will be scheduled for a telephone interview lasting approximately 60-90 minutes. Eligible oncologists will be scheduled for a telephone interview lasting approximately 60 minutes.

Searching social media is another way of understanding the perceptions of prescribers and consumers of CGT, in addition to interviews being conducted under the original protocol. The results of a feasibility assessment suggested that it would be helpful to explore social media to add to the findings from the interviews. This social media study(SMS) is being conducted as a pilot study to hone methods for future explorations of social media. The pilot study will investigate and describe initial themes emerging from existing discussions related to CGT. Findings from this work will help GlaxoSmithKline to plan future work in the social media landscape.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Neoplasms

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

GSK Investigational Site

Collegeville, Pennsylvania, 19426, United States

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

For cancer subjects:

  • Adults 18 years of age and older of any, sex, racial/ethnic group, or economic status
  • With a self-reported diagnosis of non-small-cell lung carcinoma (NSCLC), soft tissue sarcomas, or hematological malignancies
  • Willing and able to participate in a telephone interview
  • Willing to be audio-recorded during the interview session

For Oncologists:

  • Education credentials equivalent to Doctor of Medicine (MD)
  • Oncologist/hematologist-oncologist with at least five years of experience in oncology
  • Able to fluently read, speak, and understand English to participate in an interview and/or complete all assessments
  • Willing and able to participate in a telephone interview
  • Willing to be audio-recorded during the interview session

Exclusion criteria

For cancer subjects:

  • Diagnosed with cancer less than a year ago or those on first line of treatment at the time of the interview
  • Unable to provide information on their line of treatment
  • Significant speech impairment, cognitive impairment, hearing difficulty, visual impairment, or severe psychopathology (according to the opinion of the screener)
  • Any clinically-relevant medical condition including, but not limited to, severe co-morbid condition, severe mental illness, substance abuse, cognitive, or other impairment (e.g., visual) which, in the opinion of the investigator, would interfere with participating in an interview and/or completing the study procedures.

For Oncologists:

  • Currently unable to practice medicine and/or treat subjects, for reasons including (but not limited to): expired medical license, revoked medical license, or part of the Food and Drug Administration (FDA) debarment list.

Treatment and study plan

Telephonic interview

Other

Subjects with cancer and Oncologists will undergo a semi-structured one-to-one telephonic interview for up to 90 and 60 minutes respectively.

Primary outcomes

  1. Number of subjects with feedback as having benefit of CGT during interview

    Time frame: Up to 90 minutes

    Telephonic interview will be conducted to assess preliminary understanding about subjects perceptions of CGT, especially TCR and CAR T-Cell therapies in the treatment of cancer.

  2. Number of subjects with feedback as having concerns of CGT during interview

    Time frame: Up to 90 minutes

    Telephonic interview will be conducted to assess preliminary understanding about subjects perceptions of CGT, especially TCR and CAR T-Cell therapies in the treatment of cancer.

  3. Number of subjects with feedback as having fear of CGT during interview

    Time frame: Up to 90 minutes

    Telephonic interview will be conducted to assess preliminary understanding about subjects perceptions of CGT, especially TCR and CAR T-Cell therapies in the treatment of cancer.

  4. Number of subjects with willingness to be treated with CGTs

    Time frame: Up to 90 minutes

    Telephonic interview will be conducted to assess preliminary understanding about subjects perceptions of CGT, especially TCR and CAR T-Cell therapies in the treatment of cancer.

  5. Number of physicians who would initiate potential referrals to utilize CGT therapies

    Time frame: Up to 60 minutes

    Telephonic interview will be conducted to assess preliminary understanding about physicians perceptions of CGT, especially TCR and CAR T-Cell therapies in the treatment of cancer.

  6. Number of physicians with decisions to use CGT in subjects with cancer

    Time frame: Up to 60 minutes

    Telephonic interview will be conducted to assess preliminary understanding about physicians perceptions of CGT, especially TCR and CAR T-Cell therapies in the treatment of cancer.

  7. Number of physicians with concerns to use CGT in subjects with cancer

    Time frame: Up to 60 minutes

    Telephonic interview will be conducted to assess preliminary understanding about physicians perceptions of CGT, especially TCR and CAR T-Cell therapies in the treatment of cancer.

  8. Number of physicians with feedback as CGT sound better than other types of cancer treatments

    Time frame: Up to 60 minutes

    Telephonic interview will be conducted to assess preliminary understanding about physicians perceptions of CGT, especially TCR and CAR T-Cell therapies in the treatment of cancer.

  9. Number of physicians with feedback as CGT sound more concerning than other types of cancer treatments

    Time frame: Up to 60 minutes

    Telephonic interview will be conducted to assess preliminary understanding about physicians perceptions of CGT, especially TCR and CAR T-Cell therapies in the treatment of cancer.

  10. Number of physicians with feedback of recommending CGT in the future

    Time frame: Up to 60 minutes

    Telephonic interview will be conducted to assess preliminary understanding about physicians perceptions of CGT, especially TCR and CAR T-Cell therapies in the treatment of cancer.

Sponsors and collaborators

Lead sponsor

GlaxoSmithKline

Industry

Registry information

Official study title

Understanding Patients and Prescriber Perceptions of Cell and Gene Therapy (CGT) in Oncology

Important dates

Study start
2017
Primary completion
2018
Study completion
2018
First posted
Nov 8, 2017
Registry last updated
Feb 5, 2019

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.